Cervical Cancer

Latest News

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.
Toripalimab Combo Yields Responses in Metastatic Cervical Cancer

March 28th 2023

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.

According to phase 1b/2 HPV001 study data, VTP-200 appears to produce no serious adverse effects in patients with low-grade cervical human papillomavirus lesions.
Novel IO Yields ‘Encouraging’ Immunogenicity in Cervical HPV-Related Lesions

March 21st 2023

The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.
European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical Cancer

November 23rd 2022

ATG-008 combined with toripalimab produced an objective response rate of 52.4% among patients with relapsed or metastatic cervical cancer in the phase 1/2 TORCH-2 study.
ATG-008/Toripalimab Yields Promising Responses in Relapsed/Metastatic Cervical Cancer

November 16th 2022

Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical Cancer
Vaccine-Chemoradiotherapy Combo Produces 100% Clinical Response in Advanced Cervical Cancer

November 15th 2022

More News